secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-12-29T23:59:59+00:00
Accession:  0001104659-23-130516
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome CFO Corleen Roche departs; Max Rosett named Interim CFO; Bob Lapetina named principal accounting officer
--------------------------------------------------------------------------------

- CFO Corleen Roche separates effective Jan 2, 2024; receives 10.5 months salary continuation, $75,000 cash, COBRA coverage, and one-year option exercise extension.
- Roche to provide consulting from Jan 2 to Apr 5, 2024 at $300/hour; equity continues vesting during consulting period.
- Max Rosett appointed Interim CFO and principal financial officer; he has served as SVP Operations since Oct 2023.
- Bob Lapetina appointed principal accounting officer; is VP Finance & Corp Controller since May 2021; eligible for two $15,000 retention bonuses through 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/0001104659-23-130516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/tm2333682d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-130516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer